Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

83 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Correlation analysis between estimated renal function and biological half life of 131-I during radioiodine treatment of patients with differentiated thyroid cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

NCT02393690

Metastatic Thyroid Gland Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma +8 more

COMPLETED PHASE2

Iodine I 131 in Treating Patients With Thyroid Cancer

NCT00416949

Head and Neck Cancer

TERMINATED NA

The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma

NCT07314255

PTC I-131 Trop2

ACTIVE_NOT_RECRUITING

Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.

NCT00001730

Hypothyroidism Thyroid Neoplasms

COMPLETED PHASE4

Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.

NCT06134830

Thyroid Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

131-I during radioiodine treatment of patients with differentiated thyroid cancer is mainly renally excreted. It is advised in the clinical guidelines that serum creatinine should be determined before applying 131-I and if necessary the administered dose should be reduced. Nevertheless no guideline gives advice in what extent the dose should be decreased. The adjustment is at the discretion of the attending physician.

Aim of this prospective study is to correlate the biological half life of 131-I with the renal function to give objective recommendations concerning the reduction of the applied dose in patients with limited renal function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with differentiated thyroid carcinoma
* stationary for treatment or diagnostic with radioiodine
* state after thyroidectomy
* written consent of the patient
* minimum age 18 years

Exclusion Criteria

* no written consent of the patient
* patients with large residual thyroid tissue (iodine uptake \> 10%)
* children under 18 years of age
* inclusion in concurrent interventional studies
* patients without TSH-stimulation by rhTSH

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No